Erasca names Charles Fuchs as President of Research & Development
The oncologist and former Genentech/Roche executive joined the biotech effective August 10, 2026, with an equity package including 1,300,000 stock options.
SEC filing
Latest
2 stories
Monday, August 10
Thursday, August 6
CytomX reports Q2 2026 results, advances Varseta-M toward first registrational study
CytomX said enrollment in its lead ADC's Phase 1 trial is finished and it plans to start a registrational study in the first half of 2027, alongside an expanded Regeneron deal.
SEC filing